Drugs / DAS181
DAS181
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01173224 | Nov 2010 → Jun 2011 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00876161 | May → Dec 2009 | — | Ansun Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00527865 | Oct 2007 → Dec 2008 | influenza | Ansun Biopharma, Inc. | Completed | No outcome recorded |
| Phase 25 trials · 1 missed | ||||||
| Phase 2 | NCT04298060 | Jul 2020 → Mar 2021 | COVID-19–associated multisystem inflammatory syndrome in adults, influenza | Ansun Biopharma, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT01644877 | Mar 2014 → Dec 2016 | parainfluenza infectious disease | Ansun Biopharma, Inc. | Completed | Missed primary |
| Phase 2 | NCT01924793 | Aug 2013 → May 2017 | parainfluenza infectious disease | Ansun Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01740063 | Nov 2012 → Jan 2014 | influenza | Ansun Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01441024 | Jul 2011 → Feb 2014 | parainfluenza infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04354389 | Jul → Sep 2020 | COVID-19 | Ansun Biopharma, Inc. | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03808922 | May 2019 → Sep 2028 expected | COVID-19, immunodeficiency disease, parainfluenza infectious disease, respiratory tract infectious disorder | Ansun Biopharma, Inc. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04324489 | Mar → Apr 2020 | COVID-19 | Renmin Hospital of Wuhan University | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01651494 Comparator | Aug 2011 → Sep 2012 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01113034 Comparator | Jul 2010 → Aug 2011 | asthma, bronchiectasis | Ansun Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01037205 Comparator | Dec 2009 → Sep 2011 | influenza | Ansun Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAS181 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01037205 ↗ |
| Known as | DAS-181-F04 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297932 ↗ |
| Known as | Fludase | “DAS181, (study drug, Fludase®) was developed for treatment of influenza and parainfluenza infections.” PMID 26391974 ↗ Sep 20151“This study will assess the safety of a new study drug called DAS181 (Fludase®).” NCT01113034 ↗ |
| Known as | Oplunofusp | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297932 ↗ |
| Action | Inhibit | “selectively cleaves sialic acids from the host cells, thereby rendering them inaccessible to the influenza viral particles that require sialic acids as receptors” NCT01173224 ↗ |
| Modality | Protein / enzyme biologic | “an inhaled sialidase” PMID 26391974 ↗ Sep 2015 |
| Route | Inhaled | “Delivered by inhalation” PMID 26391974 ↗ Sep 2015 |